Middle ear fluid (MEF) levels of cefpodoxime in pediatric patients with acute otitis media (AOM)

M. T. Borin, D. P. McCormick, R. H. Schwartz, K. K. Ryan

Research output: Contribution to journalArticle

Abstract

The penetration of cefpodoxime into the middle ear of 26 pediatric patients (age, 6 mo to 9 yr) with AOM was evaluated after administration of cefpodoxime proxetil oral suspension 5 mg/kg bid or 10 mg/kg qd. After at least one complete day of treatment, tympanocentesis was performed during a 2-8 hr interval after the morning dose; a blood sample was collected at the same time as the MEF. Drug concentrations in MEF and plasma were determined using a HPLC method with tandem mass selective detection. Median (range) cefpodoxime concentrations in MEF are shown in the following table: 5 mg/kg bid (N=12) 10 mg/kg qd (N=14) Collection Time(hr) n Conc(μg/mL) n Conc (μg/mL) 2-4 4 2.49 (2.0-3.3) 2 1.70 (1.5, 1.9) 4-6 5 0.50 (0.35-1.6) 6 3.24 (2.1-12.2) 6-8 7 0.97 (0.33-1.2) 8 2.21 (0.20-4.1) The MEF/plasma cefpodoxime concentration ratio ranged from 0.25 to 2.6 and from 0.13 to 3.2 in the 5 mg/kg bid and 10 mg/kg qd groups, respectively. MEF cefpodoxime levels ≥0.50 μg/mL were attained in 88% of the patients. These levels exceed the minimum inhibitory concentration for the majority of S pneumoniae, H influenzae, and M catarrhalis isolates, the most common etiological agents of AOM, and thus support cefpodoxime's utility in treating this disease.

Original languageEnglish (US)
Pages (from-to)148
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

cefpodoxime
Otitis Media
Middle Ear
Pediatrics
cefpodoxime proxetil
Microbial Sensitivity Tests
Human Influenza
Pneumonia
Suspensions
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology

Cite this

Middle ear fluid (MEF) levels of cefpodoxime in pediatric patients with acute otitis media (AOM). / Borin, M. T.; McCormick, D. P.; Schwartz, R. H.; Ryan, K. K.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 2, 1997, p. 148.

Research output: Contribution to journalArticle

Borin, M. T. ; McCormick, D. P. ; Schwartz, R. H. ; Ryan, K. K. / Middle ear fluid (MEF) levels of cefpodoxime in pediatric patients with acute otitis media (AOM). In: Clinical Pharmacology and Therapeutics. 1997 ; Vol. 61, No. 2. pp. 148.
@article{ae2d1de975564c6bbbcf91b209cf233e,
title = "Middle ear fluid (MEF) levels of cefpodoxime in pediatric patients with acute otitis media (AOM)",
abstract = "The penetration of cefpodoxime into the middle ear of 26 pediatric patients (age, 6 mo to 9 yr) with AOM was evaluated after administration of cefpodoxime proxetil oral suspension 5 mg/kg bid or 10 mg/kg qd. After at least one complete day of treatment, tympanocentesis was performed during a 2-8 hr interval after the morning dose; a blood sample was collected at the same time as the MEF. Drug concentrations in MEF and plasma were determined using a HPLC method with tandem mass selective detection. Median (range) cefpodoxime concentrations in MEF are shown in the following table: 5 mg/kg bid (N=12) 10 mg/kg qd (N=14) Collection Time(hr) n Conc(μg/mL) n Conc (μg/mL) 2-4 4 2.49 (2.0-3.3) 2 1.70 (1.5, 1.9) 4-6 5 0.50 (0.35-1.6) 6 3.24 (2.1-12.2) 6-8 7 0.97 (0.33-1.2) 8 2.21 (0.20-4.1) The MEF/plasma cefpodoxime concentration ratio ranged from 0.25 to 2.6 and from 0.13 to 3.2 in the 5 mg/kg bid and 10 mg/kg qd groups, respectively. MEF cefpodoxime levels ≥0.50 μg/mL were attained in 88{\%} of the patients. These levels exceed the minimum inhibitory concentration for the majority of S pneumoniae, H influenzae, and M catarrhalis isolates, the most common etiological agents of AOM, and thus support cefpodoxime's utility in treating this disease.",
author = "Borin, {M. T.} and McCormick, {D. P.} and Schwartz, {R. H.} and Ryan, {K. K.}",
year = "1997",
language = "English (US)",
volume = "61",
pages = "148",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Middle ear fluid (MEF) levels of cefpodoxime in pediatric patients with acute otitis media (AOM)

AU - Borin, M. T.

AU - McCormick, D. P.

AU - Schwartz, R. H.

AU - Ryan, K. K.

PY - 1997

Y1 - 1997

N2 - The penetration of cefpodoxime into the middle ear of 26 pediatric patients (age, 6 mo to 9 yr) with AOM was evaluated after administration of cefpodoxime proxetil oral suspension 5 mg/kg bid or 10 mg/kg qd. After at least one complete day of treatment, tympanocentesis was performed during a 2-8 hr interval after the morning dose; a blood sample was collected at the same time as the MEF. Drug concentrations in MEF and plasma were determined using a HPLC method with tandem mass selective detection. Median (range) cefpodoxime concentrations in MEF are shown in the following table: 5 mg/kg bid (N=12) 10 mg/kg qd (N=14) Collection Time(hr) n Conc(μg/mL) n Conc (μg/mL) 2-4 4 2.49 (2.0-3.3) 2 1.70 (1.5, 1.9) 4-6 5 0.50 (0.35-1.6) 6 3.24 (2.1-12.2) 6-8 7 0.97 (0.33-1.2) 8 2.21 (0.20-4.1) The MEF/plasma cefpodoxime concentration ratio ranged from 0.25 to 2.6 and from 0.13 to 3.2 in the 5 mg/kg bid and 10 mg/kg qd groups, respectively. MEF cefpodoxime levels ≥0.50 μg/mL were attained in 88% of the patients. These levels exceed the minimum inhibitory concentration for the majority of S pneumoniae, H influenzae, and M catarrhalis isolates, the most common etiological agents of AOM, and thus support cefpodoxime's utility in treating this disease.

AB - The penetration of cefpodoxime into the middle ear of 26 pediatric patients (age, 6 mo to 9 yr) with AOM was evaluated after administration of cefpodoxime proxetil oral suspension 5 mg/kg bid or 10 mg/kg qd. After at least one complete day of treatment, tympanocentesis was performed during a 2-8 hr interval after the morning dose; a blood sample was collected at the same time as the MEF. Drug concentrations in MEF and plasma were determined using a HPLC method with tandem mass selective detection. Median (range) cefpodoxime concentrations in MEF are shown in the following table: 5 mg/kg bid (N=12) 10 mg/kg qd (N=14) Collection Time(hr) n Conc(μg/mL) n Conc (μg/mL) 2-4 4 2.49 (2.0-3.3) 2 1.70 (1.5, 1.9) 4-6 5 0.50 (0.35-1.6) 6 3.24 (2.1-12.2) 6-8 7 0.97 (0.33-1.2) 8 2.21 (0.20-4.1) The MEF/plasma cefpodoxime concentration ratio ranged from 0.25 to 2.6 and from 0.13 to 3.2 in the 5 mg/kg bid and 10 mg/kg qd groups, respectively. MEF cefpodoxime levels ≥0.50 μg/mL were attained in 88% of the patients. These levels exceed the minimum inhibitory concentration for the majority of S pneumoniae, H influenzae, and M catarrhalis isolates, the most common etiological agents of AOM, and thus support cefpodoxime's utility in treating this disease.

UR - http://www.scopus.com/inward/record.url?scp=33748968699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748968699&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 148

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -